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• True ureteral and renal pelvis metastases are rarely present.
• The separation of metastatic colorectal carcinoma from primary adenocarcinoma of the urinary tract 
can pose diagnostic difficulties.
Novel Insights
• This is the first case reported with concurrent ureteral and renal pelvis metastases of colorectal adeno-
carcinoma.
• In our experience, DNA sequencing proved to be a safe diagnostic tool to differentiate between pri-
mary and metastatic adenocarcinoma of the urinary tract.
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Abstract
Introduction: Secondary urinary tract tumors are uncommon 
findings and mainly evolve by direct invasion from adjacent 
organs. Actual metastatic involvement often develops in the 
urinary bladder, while the upper urinary tract is infrequently 
affected. In addition, the lungs, breast, and prostate gland 
are the usual primary sites. Colorectal carcinoma (CRC) may 
spread to the ureter directly or seeds via vascular or lym-
phatic channels. It may pose struggles in the differential di-
agnosis because CRC shares standard pathologic features 
with the primary adenocarcinoma of the urinary tract. Case 
Presentation: We describe the case of an 81-year-old man 
who was referred to our hospital with a distal ureteral tumor 
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that was treated by a ureteronephrectomy. The histopatho-
logical and genetic analysis established the diagnosis of 
metastatic CRC along with 3 metastases in the renal pelvis. 
Conclusion: This rare case highlights the limitations of 
conventional histological processing, including immunohis-
tochemistry, and it underlines the role of molecular investi-
gations in certain circumstances. © 2021 The Author(s).
Published by S. Karger AG, Basel
Introduction
The obstruction of the ureter by direct invasion of 
retroperitoneal or minor pelvic tumors is relatively fre-
quent. In contrast, the development of a true ureteral 
metastasis from distant primary tumors (such as the 
lung, breast, and prostate gland) is an unusual event, 
with approximately 400 cases reported [1]. According-
ly, CRC may invade the distant section of the ureter di-
rectly or via lymphatic channels and blood vessels [2], 
but hematogenous metastasis to the renal pelvis is a 
scarce event with rare case reports in the English litera-
ture [3]. Nevertheless, no data were found regarding the 
phenomenon of the concurrent renal pelvis and ure-
teral metastases in disseminated CRC. Of note, meta-
static involvement of the ureter is frequently associated 
with extensive tumor burden; hence, it is often diag-
nosed postmortem [4]. The diagnosis of metastatic 
CRC of the ureter is usually based on the clinical data 
and the exclusion of primary ureteral tumors. Immuno-
histochemically, there are no decisive markers; hence, 
the pathological diagnosis can be challenging [5]. Here, 
we report the coexistence of both ureteral and renal pel-
vis metastasis of a CRC.
Case Report
Here, an 81-year-old male patient with left-sided hydrone-
phrosis was admitted to our institution. Two years ago, a sigmoid 
colon carcinoma was discovered and treated by a left hemicolectomy. 
The pathological analysis revealed an intestinal-type adenocarci-
noma with pT3pN1a pathological stage. Moreover, extensive tumor 
budding along with lymphovascular invasion was observed. The 
molecular investigations carried out identified a KRAS mutation 
in codon 12 (G12D). The patient received adjuvant chemotherapy 
with 6 cycles of capecitabine, which was tolerated well, and no 
significant side effects were recorded. The follow-up from May 
2019 to September 2020 was uneventful. Then, the patient com-
plained of hematuria, and, at first, a cystoscopy was carried out that 
described no bladder tumor, inflammation, or stone but noticed 
blood leakage from the left ureteral orifice. Additionally, a rigid 
ureteroscopy was unsuccessful; therefore, any histological sam-
pling or upper urinary tract washing for cytology was impossi-
ble. The next step was a contrast-enhanced abdominal CT, 
which showed a distal ureteral mass causing severe, grade IV, 
left-sided hydronephrosis with thinned, impaired renal paren-
chyma (Fig. 1a). At the multidisciplinary team meeting, the le-
sion was considered a primary ureteral urothelial cell carcinoma 
(UCC). As no additional information was expected from another 
imaging technique, a presumably curative surgery was decided. 
Consequently, a left-sided ureteronephrectomy and lymph node 
dissection were carried out. The surgery and the postoperative 
period were uneventful. After a 2-month-long recovery, as part 
of restaging examinations, a whole-body FDG PET/CT was per-
formed that described lytic metastasis in the body of vertebra 
VII, seventh rib on the left side, and parietal bones, but it did 
not prove other distant metastasis or local recurrence. Palliative 
radiotherapy with a 10 × 3 Gy total dose was planned, but 
due to the severe acute respiratory distress syndrome caused by 
COVID-19 infection, the patient deceased just 67 days after the 
surgery.
Pathological Findings
The gross analysis of the ureteronephrectomy specimen re-
vealed a 60-mm large tumor in the distal part of the ureter along 
with 3 masses in the renal pelvis (Fig. 1b). Also, severe dilation 
of the urinary tract was observed, and there was a macroscopi-
cally evident resection line positivity. The histological investiga-
tion identified these lesions as intestinal-type adenocarcinomas 
with the typical cribriform pattern and dirty necrosis in their 
lumina. The ureteral tumor affected all layers and destroyed 
most of the surface urothelium (Fig. 1c, d). Two tumors had an 
exophytic growing pattern in the pelvis, while 1 lesion infiltrated 
the renal parenchyma and renal sinus (Fig. 2a–c). Here, the uro-
thelium showed no sign of dysplasia; besides, no glandular meta-
plasia was observed (Fig. 2d). The tumor cells were present in 
the circumferential resection line; furthermore, in the lymph 
nodes harvested, the metastasis of the same adenocarcinoma was 
seen. We applied immunohistochemical studies to clarify the 
origin of the tumors. The results were as follows: all tumors and 
the lymphatic metastasis were positive with CK20 and CDX2 in 
a diffuse fashion (Fig. 2e, f); besides, the CK7 and GATA3 stain-
ing was negative. Interestingly, we experienced a diffuse and 
membranous beta-catenin expression in the samples examined 
(Fig. 2g), and we observed this membranous pattern in the pre-
vious colonic adenocarcinoma. At this point, the exact origin of 
the neoplasms was still uncertain since both the light micros-
copy and the immunohistochemical analysis were inconclusive. 
A KRAS sequencing was ordered from the tumors in the renal 
pelvis, ureter, and lymph node. The molecular pathological exami-
nation identified a pathological mutation in codon 12 (G12D) in 
all tumors (Fig. 2h). A microsatellite instability analysis was ad-
ditionally requested that revealed a stable microsatellite status. 
After a 2-month-long recovery, a whole-body FDG PET/CT has 
been scheduled that described lytic metastasis in the body of ver-
tebra VII, seventh rib on the left side, and parietal bones. Pallia-
tive radiotherapy with a 10 × 3 Gy total dose was planned, but 
due to the severe acute respiratory distress syndrome caused by 
COVID-19 infection, the patient deceased just 67 days after the 
surgery.





Here, a patient with an assumed UCC of the distal ure-
ter underwent ureteronephrectomy, and the histological 
analysis uncovered coexisting ureteral and renal pelvis 
metastases originating from the previous colon adenocar-
cinoma. Here, we discuss the possible mechanisms of the 
observed phenomenon and diagnostic pitfalls.
Metastatic tumors can invade the ureter by direct 
extension and via vascular or lymphatic channels [2]. 
Regarding the former mechanism, cervical cancer is 
the most frequent reason, followed by CRC and other 
retroperitoneal tumors like lymphoma, liposarcoma, 
etc. [6]. On the other hand, a true distant metastasis to 
the ureter is an unusual phenomenon. The primary tumor 
is mostly discovered in the lungs, breast, prostate gland, 
and sometimes in the colon [7]. Clinically, unilateral or 
bilateral hydronephrosis is the usual complication ex-
perienced in these cases, and the obstruction usually 
results from an outside compression rather than a real 
invasion [8]. In addition, hematuria is seldom noticed 
because the urothelium mostly remains intact [8]. In-
terestingly, in cases of true metastatic involvement, the 
lower third part of the ureter is typically affected. In our 
case, we experienced a slightly different clinical scenario 
because the ureteral metastasis showed transmural in-
volvement. Uniquely, the urothelium itself was destroyed 
or focally replaced by the tumor cells; therefore, similar 
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Fig. 1. Radiological and pathological features 
of the case presented. a Axial enhanced ab-
dominal CT scan (soft tissue window) shows 
an inhomogeneous, contrast-enhanced, 
lobulated lesion (30 × 41 × 32 mm) in the low 
third segment of the left ureter, causing an 
obstruction and severe hydronephrosis. In 
this case, the hydronephrosis is grade 4. 
The dilatation of the renal pelvis and caly-
ces with cortical thinning indicates an ir-
reversible renal functional loss. The renal 
pelvis metastasis (yellow arrow) accumu-
lates the intravenous contrast agent better 
than the damaged renal parenchyma in the 
venous phase. b The corresponding macro-
scopic picture demonstrates the hydroure-
ter along with hydronephrosis. The black 
arrow points at a lesion that originates from 
the renal pelvis, but signs of parenchymal 
invasion are present. Additionally, the red 
arrow indicates the tumor obstructing the 
lower third part of the ureter. c In the cross-
section of the ureter, an invasive carcinoma 
with transmural and mucosal infiltration 
can be seen. The asterisk illustrates the lu-
men of the ureter. The image has a magnifi-
cation factor of ×7. d Most of the inner sur-
face of the ureter was ulcerated; however, in 
some areas, atypical glandular proliferation 










Fig. 2. Histological, immunohistochemical, and genetic features 
observed. a This renal pelvis metastasis has a flat appearance along 
with the invasion of the adjacent renal parenchyma. The image has 
a magnification factor of ×10. b, c These pictures represent the oth-
er 2 metastatic tumors with exophytic growth. The images have a 
magnification factor of ×2. d The urothelium in proximity (arrows) 
shows neither glandular metaplasia nor dysplasia. The image has a 
magnification factor of ×20. e–g The tumor cells express in a diffuse 
fashion CK20, CDX2, and beta-catenin, respectively. Regarding the 
latter one, no nuclear staining was experienced. The images have a 
magnification factor of ×4, ×8, and ×40, respectively. h The hot 
spots of exon 2 of the KRAS gene (codons 12–13) were amplified by 
PCR, and the nucleotide sequence was determined by Sanger capil-
lary sequencing. The sequencing identified a G12D (c.35 G > A) 
mutation, one of the most common mutations. The figure indicates 
the representative sequence of the ureter metastasis.




to primary urinary tract neoplasms, hematuria was no-
ticed. It is important to note that the metastatic in-
volvement of the ureter is usually asymptomatic. In 
symptomatic cases, the signs are often nonspecific, like 
back pain, dysuria, frequent urination, etc. [4].
In the sigmoid adenocarcinoma resected, there was 
an extensive lymphovascular invasion along with a 
broad tumor budding. Although the exact mechanism 
and risk factors are still not characterized, we suggest 
that the invasive nature of the primary tumor may ex-
plain the development of this ureteral metastasis 
through the rich lymphatic network of the periureteral 
soft tissue.
A metastatic spread to the renal pelvis is an extraor-
dinary phenomenon with solely anecdotal cases re-
ported, and the lung is the most important site for the 
primary tumor [9]. In our case, 3 metastases were iden-
tified in the renal pelvis, and among the ureteral and 
renal pelvis tumors, apart from flattening and thin-
ning, the urothelium was intact. Considering the link 
between these changes, first, we should speculate on a 
further lymphatic spread of the ureteral tumor toward 
the renal pelvis. However, all sections of the ureter have 
their transverse lymphatic circulation, so dissemina-
tion from the distal part of the ureter to the renal pelvis 
seems impossible. Second, it is a well-known and ac-
cepted fact that renal pelvis UCC might involve the dis-
tal region of the urinary tract by drop metastasis [10]. 
Also, there are reports on drop metastasis from renal 
cell carcinoma to the distal part of the genitourinary 
system [11]. In our patient, the ureter tumor caused an 
obstruction leading to hydroureter and hydronephro-
sis, and we hypothesize that a reflux mechanism was 
responsible for the tumor cell seeding and implanta-
tion. Also, it was earlier demonstrated that the previ-
ously traumatized urothelium was more vulnerable to 
drop metastasis [12].
Cystoscopy is the standard procedure in patients with 
assumed bladder cancer, while ureteroscopy can access 
the upper urinary tract [13]. Concerning the latter one, 
rigid and flexible devices are available. Rigid ureteros-
copy provides a better perceptibility and enables the use 
of supplementary components, but the entry to the ure-
ter is sometimes problematic or even impossible [13]. 
Flexible ureteroscopy can be an alternative; however, 
these devices are more expensive and need additional 
instruments [13]. Both technics may provide a solid diag-
nosis of the underlying condition; furthermore, a curative 
surgical resection might be performed or biopsy samples 
may be harvested for histological examination [13]. 
Also, these samples are fit for biomarker testing (i.e., 
PD-L1 immunohistochemistry) or genetic analysis. On 
the other hand, urine cytology is an alternative to detect 
or screen urinary tract cancer. Most frequently, voided 
urine is used because this is the easiest to obtain, but the 
sample is usually paucicellular [13]. For cytological anal-
ysis, instrumented urine or urine from ileal conduit can 
be investigated as well. Regarding the former one, cel-
lularity is usually appropriate, although instrumentation 
artifact may lead to a false-positive result [13]. In gen-
eral, urine cytology is an adequate and sensitive diag-
nostic tool for high-grade tumors, but it is less sensitive 
for low-grade lesions [13]. Of note, by applying addi-
tional technics like UroVysion FISH, the sensitivity can 
be improved [13]. In our case, the rigid ureteroscopy was 
not successful; thereby, no pathological diagnosis was 
established before the ureteronephrectomy.
From a pathological standpoint of view, in our case, 
the main differential diagnostic consideration was the 
primary adenocarcinoma of the ureter and the renal 
pelvis. This kind of tumor is mostly diagnosed in the 
urinary bladder and exceedingly rare in the sites men-
tioned above [14]. Also, the diagnosis of the primary 
adenocarcinoma in the urinary bladder is usually made 
by exclusion since no specific markers for the distinc-
tion from metastatic CRC exist [15]. Some authors sug-
gest the use of β-catenin staining due to lack of nuclear 
expression in primary urinary tract adenocarcinoma 
[16]; however, in our case, β-catenin was useless be-
cause both the primary and metastatic tumors showed 
a membranous positivity pattern. Conventional markers 
like CK7, CK20, GATA3, and CDX2 also have limited di-
agnostic value [15].
On the other hand, nearby the primary urinary tract 
adenocarcinoma, glandular metaplasia may be present 
in the urothelium; therefore, a comprehensive sampling 
and a careful investigation of the adjacent urothelium is 
advised [17]. In our case, the entire ureter was pro-
cessed, and the changes as mentioned earlier were ex-
perienced neither in the ureteral tumor nor in the renal 
pelvis metastases. If the histological material is suitable, 
genetic testing might be a reliable tool for distinction. 
Notably, molecular tests have the best accuracy when 
the known mutation of a primary tumor is looked for. 
The genetic background of the UCC is extensively in-
vestigated and documented, but, in contrast, the genet-
ic landscape of urinary tract adenocarcinomas is less 
known. Earlier, low-frequency KRAS and TERT pro-
moter region mutations were identified in urinary tract 





of TP53, RB1, PIK3CA, and RB1, too [18]. Of note, the 
genetic changes described partly overlap with UCC and 
CRC, but their frequency varies. For instance, TERT 
promoter region mutation is present in approximately 
80% of bladder UCC cases; however, it is found only in 
13%–28.5% in bladder adenocarcinomas [18]. Also, ap-
proximately 30%–40% of CRC shows KRAS mutation, 
while up until now, in bladder adenocarcinoma, an 
11.3% frequency was described [18, 19]. Additionally, 
KRAS and NRAS are routinely investigated before anti-
EGFR therapy in metastatic CRC; therefore, we ordered 
a KRAS testing of the ureteral tumor. In our case, mo-
lecular testing was particularly useful because the same 
pathogenic mutation of the KRAS gene was identified 
in every tumor tissue sequenced. As stated earlier, there 
are some reports on KRAS mutation in urinary tract 
adenocarcinoma [18]. However, in our case, all the sam-
ples investigated (primary colorectal carcinoma, ureteral 
tumor, 3 renal pelvis tumors, and lymphatic metastasis) 
harbored the same mutation, and the chance to exist the 
same mutation in 4 different tumors seems to be dubi-
ous. Besides the abovementioned genetic alterations, 
primary urinary tract adenocarcinoma may harbor mi-
crosatellite instability that can be investigated by immu-
nohistochemistry or PCR testing [20]. In our case, we 
used MLH1, MSH2, MSH6, and PMS2 immunostain-
ings, and there was a strong retained expression of all 
the proteins mentioned above in the tumor cells; thus, 
the tumor was microsatellite stable. In the differential 
diagnosis, UCC with glandular differentiation should 
be regarded too. However, first, this feature usually 
presents in up to approximately 10–20% of the cases, 
and second, the glandular component is found within 
the conventional UCC. Last, these tumors are normally 
characterized by a strong CK7 positivity along with a 
variable CDX2, SATb2, and Cadherin17 expression 
[21]. The histological appearance and the immunopro-
file of our case were not in harmony with the previous 
features, and therefore UCC with glandular differentia-
tion was excluded.
Metastatic adenocarcinoma of the urinary tract 
could show various histological features depending on 
the primary tumor type; therefore, the clinical data ob-
tained on any previous malignancy are crucial for the 
diagnosis [6]. It is also necessary to use the immunohis-
tochemical markers in combination. According to our 
practice, an antibody panel containing CK7, GATA3, 
CK20, PAX8, TTF1, CDX2, and NKX3.1 (for males) or 
mammaglobin (for females) seems to be suitable for 
covering not only UCC but also the most frequent met-
astatic adenocarcinomas.
In conclusion, we presented a case of coexisting ure-
teral and renal pelvis metastases coming from colon 
adenocarcinoma. This is the first case reported with 
such a unique constellation in metastatic CRC to the 
best of our knowledge. Its distinction from the primary 
adenocarcinoma of the urinary tract is essential to 
reach excellent patient care. Although molecular ge-
netic testing can be of limited value, DNA sequencing 
might be a powerful diagnostic tool in well-selected 
cases.
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